Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528338 | 0.85 | GRIN2B (0.45) | GRIN1GRIN2BMEN1KMT2ATP53 | |
| SCHEMBL23528283 | 0.82 | SCN5A (0.46) | SCN5AMETMEN1KMT2ATP53 | |
| SCHEMBL23528311 | 0.82 | SCN1A (0.46) | GRIN1GRIN2BSCN5AMETMEN1 | |
| SCHEMBL23528355 | 0.80 | MET (0.46) | METMEN1KMT2ATP53MAPT | |
| SCHEMBL26999077 | 0.80 | MEN1 (0.46) | METMEN1KMT2ATP53MAPT | |
| SCHEMBL23528292 | 0.80 | MEN1 (0.40) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL23528312 | 0.80 | MEN1 (0.40) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL26999085 | 0.80 | GRIN1 (0.47) | GRIN1GRIN2BMETMEN1KMT2A | |
| SCHEMBL26999079 | 0.79 | MEN1 (0.40) | GRIN1GRIN2BMEN1KMT2ATP53 | |
| SCHEMBL23528295 | 0.79 | GRIN1 (0.47) | GRIN1GRIN2BSCN5AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873290-B2 | — | IL6, MUSK, IL6ST | GRIN1 959/4885GRIN2B 2129/4885SCN5A 1130/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | GRIN1 894/4885GRIN2B 1997/4885SCN5A 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.